Drugmaker Merck announced Monday that it submitted an application to the FDA for emergency use authorization of molnupiravir, an experimental antiviral COVID-19 treatment.
If the FDA grants authorization, the drug would be the first oral antiviral treatment for COVID-19. The capsule, made by Merck and Ridgeback Biotherapeutics, is intended to treat mild to moderate COVID-19 in adults who are at risk of having severe COVID-19 or hospitalization.
Read more here : https://www.medscape.com/viewarticle/960638?uac=218819SG&faf=1&sso=true&impID=3705187&src=mkm_covid_update_211011_MSCPEDIT
Comments